keynote-365: pembrolizumab combination therapy for mcrpc
Published 4 years ago • 82 plays • Length 4:15
Download video MP4
Download video MP3
Similar videos
-
2:38
keynote-365 cohort a: pembrolizumab plus olaparib in docetaxel-pretreated patients with mcrpc
-
2:54
updated analysis of keynote-199: pembrolizumab for mcrpc previously treated with docetaxel
-
3:18
keynote-199: an update on pembrolizumab for mcrpc
-
2:58
evan yu, md, elaborates on the results from keynote 365 in mcrpc
-
1:15
dr. yu on rationale for the keynote-365 study in mcrpc
-
3:57
pembrolizumab plus 5-fu and cisplatin for first-line treatment in...
-
2:03
key takeaways from keynote-365 in metastatic castration-resistant prostate cancer
-
1:53
william oh, md, tells us about the results of keynote-365 in mcrpc
-
1:14
dr. yu on combining pembrolizumab and olaparib in mcrpc
-
0:45
sumit k. subudhi, md, phd, considers the outcomes of the keynote 365 study
-
1:26
nicholas vogelzang, md, fasco, facp, offers his impression of keynote 365 in mcrpc
-
1:06
leap-011: first-line pembrolizumab plus lenvatinib for uc
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
8:23
results from a phase i study of amg 160
-
38:47
parp inhibitors and their evolving role for the treatment of prostate cancer
-
2:23
daniel petrylak, emso 2019 - phase iii keynote-321 study in prostate cancer
-
0:42
elisabeth heath, md, facp, offers perspective on the keynote-365 clinical study
-
8:45
keynote-590: pembrolizumab plus chemotherapy for advanced oesophageal cancer
-
1:30
vbir vaccine shows promise in prostate cancer: phase i trial results and immunotherapy potential
Clip.africa.com - Privacy-policy